These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 26230382)

  • 1. Pharmacogenetic versus clinical dosing of warfarin in individuals of Chinese and African-American ancestry: assessment using data simulation.
    Syn NL; Lee SC; Brunham LR; Goh BC
    Pharmacogenet Genomics; 2015 Oct; 25(10):491-500. PubMed ID: 26230382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CYP2C9*8 is prevalent among African-Americans: implications for pharmacogenetic dosing.
    Scott SA; Jaremko M; Lubitz SA; Kornreich R; Halperin JL; Desnick RJ
    Pharmacogenomics; 2009 Aug; 10(8):1243-55. PubMed ID: 19663669
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Poor warfarin dose prediction with pharmacogenetic algorithms that exclude genotypes important for African Americans.
    Drozda K; Wong S; Patel SR; Bress AP; Nutescu EA; Kittles RA; Cavallari LH
    Pharmacogenet Genomics; 2015 Feb; 25(2):73-81. PubMed ID: 25461246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estimation of the warfarin dose with a pharmacogenetic refinement algorithm in Chinese patients mainly under low-intensity warfarin anticoagulation.
    Xu Q; Xu B; Zhang Y; Yang J; Gao L; Zhang Y; Wang H; Lu C; Zhao Y; Yin T
    Thromb Haemost; 2012 Dec; 108(6):1132-40. PubMed ID: 23015069
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of CYP2C9 and VKORC1 on warfarin response during initiation of therapy.
    Limdi NA; Wiener H; Goldstein JA; Acton RT; Beasley TM
    Blood Cells Mol Dis; 2009; 43(1):119-28. PubMed ID: 19297219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors influencing pharmacokinetics of warfarin in African-Americans: implications for pharmacogenetic dosing algorithms.
    Nagai R; Ohara M; Cavallari LH; Drozda K; Patel SR; Nutescu EA; Perera MA; Hernandez W; Kaneko N; Hibiya M; Takahashi H
    Pharmacogenomics; 2015; 16(3):217-25. PubMed ID: 25712185
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population differences in S-warfarin pharmacokinetics among African Americans, Asians and whites: their influence on pharmacogenetic dosing algorithms.
    Kubo K; Ohara M; Tachikawa M; Cavallari LH; Lee MTM; Wen MS; Scordo MG; Nutescu EA; Perera MA; Miyajima A; Kaneko N; Pengo V; Padrini R; Chen YT; Takahashi H
    Pharmacogenomics J; 2017 Dec; 17(6):494-500. PubMed ID: 27503578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differences in Warfarin Pharmacodynamics and Predictors of Response Among Three Racial Populations.
    Ohara M; Suzuki Y; Shinohara S; Gong IY; Schmerk CL; Tirona RG; Schwarz UI; Wen MS; Lee MTM; Mihara K; Nutescu EA; Perera MA; Cavallari LH; Kim RB; Takahashi H
    Clin Pharmacokinet; 2019 Aug; 58(8):1077-1089. PubMed ID: 30815847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chinese Patients With Heart Valve Replacement Do Not Benefit From Warfarin Pharmacogenetic Testing on Anticoagulation Outcomes.
    Hao Y; Yang J; Zheng X; Hu Y; Yan X; Zhang L
    Ther Drug Monit; 2019 Dec; 41(6):748-754. PubMed ID: 31259883
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized and clinical effectiveness trial comparing two pharmacogenetic algorithms and standard care for individualizing warfarin dosing (CoumaGen-II).
    Anderson JL; Horne BD; Stevens SM; Woller SC; Samuelson KM; Mansfield JW; Robinson M; Barton S; Brunisholz K; Mower CP; Huntinghouse JA; Rollo JS; Siler D; Bair TL; Knight S; Muhlestein JB; Carlquist JF
    Circulation; 2012 Apr; 125(16):1997-2005. PubMed ID: 22431865
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacogenetics of warfarin dosing in patients of African and European ancestry.
    Shendre A; Dillon C; Limdi NA
    Pharmacogenomics; 2018 Nov; 19(17):1357-1371. PubMed ID: 30345882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative performance of pharmacogenetics-based warfarin dosing algorithms derived from Caucasian, Asian, and mixed races in Thai population.
    Chumnumwat S; Yi K; Lucksiri A; Nosoongnoen W; Chindavijak B; Chulavatnatol S; Sarapakdi A; Nathisuwan S
    Cardiovasc Ther; 2018 Apr; 36(2):. PubMed ID: 29243335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacogenetic dosing of warfarin in the Han-Chinese population: a randomized trial.
    Wen MS; Chang KC; Lee TH; Chen YF; Hung KC; Chang YJ; Liou CW; Chen JJ; Chang CH; Wang CY; Jeng JS; Chuang HP; Chen YT; Chen CH; Wu JY; Chen YT; Lee MT
    Pharmacogenomics; 2017 Feb; 18(3):245-253. PubMed ID: 28112575
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validation of a proposed warfarin dosing algorithm based on the genetic make-up of Egyptian patients.
    Ekladious SM; Issac MS; El-Atty Sharaf SA; Abou-Youssef HS
    Mol Diagn Ther; 2013 Dec; 17(6):381-90. PubMed ID: 23839801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study.
    Perera MA; Cavallari LH; Limdi NA; Gamazon ER; Konkashbaev A; Daneshjou R; Pluzhnikov A; Crawford DC; Wang J; Liu N; Tatonetti N; Bourgeois S; Takahashi H; Bradford Y; Burkley BM; Desnick RJ; Halperin JL; Khalifa SI; Langaee TY; Lubitz SA; Nutescu EA; Oetjens M; Shahin MH; Patel SR; Sagreiya H; Tector M; Weck KE; Rieder MJ; Scott SA; Wu AH; Burmester JK; Wadelius M; Deloukas P; Wagner MJ; Mushiroda T; Kubo M; Roden DM; Cox NJ; Altman RB; Klein TE; Nakamura Y; Johnson JA
    Lancet; 2013 Aug; 382(9894):790-6. PubMed ID: 23755828
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anticoagulation endpoints with clinical implementation of warfarin pharmacogenetic dosing in a real-world setting: A proposal for a new pharmacogenetic dosing approach.
    Arwood MJ; Deng J; Drozda K; Pugach O; Nutescu EA; Schmidt S; Duarte JD; Cavallari LH
    Clin Pharmacol Ther; 2017 May; 101(5):675-683. PubMed ID: 28032893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Validation of pharmacogenetic algorithms and warfarin dosing table in Egyptian patients.
    Bazan NS; Sabry NA; Rizk A; Mokhtar S; Badary O
    Int J Clin Pharm; 2012 Dec; 34(6):837-44. PubMed ID: 22851439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacogenetic-guided Warfarin Dosing Algorithm in African-Americans.
    Alzubiedi S; Saleh MI
    J Cardiovasc Pharmacol; 2016 Jan; 67(1):86-92. PubMed ID: 26355760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The population attributable fraction as a measure of the impact of warfarin pharmacogenetic testing.
    Chan SL; Suo C; Chia KS; Teo YY
    Pharmacogenomics; 2012 Aug; 13(11):1247-56. PubMed ID: 22920395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized trial of genotype-guided dosing of warfarin.
    Pirmohamed M; Burnside G; Eriksson N; Jorgensen AL; Toh CH; Nicholson T; Kesteven P; Christersson C; Wahlström B; Stafberg C; Zhang JE; Leathart JB; Kohnke H; Maitland-van der Zee AH; Williamson PR; Daly AK; Avery P; Kamali F; Wadelius M;
    N Engl J Med; 2013 Dec; 369(24):2294-303. PubMed ID: 24251363
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.